Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) EBITDA: 2019-2024

Historic EBITDA for Lyell Immunopharma (LYEL) over the last 6 years, with Dec 2024 value amounting to -$342.6 million.

  • Lyell Immunopharma's EBITDA rose 10.88% to -$38.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$326.2 million, marking a year-over-year decrease of 61.46%. This contributed to the annual value of -$342.6 million for FY2024, which is 50.84% down from last year.
  • As of FY2024, Lyell Immunopharma's EBITDA stood at -$342.6 million, which was down 50.84% from -$227.1 million recorded in FY2023.
  • Lyell Immunopharma's EBITDA's 5-year high stood at -$189.1 million during FY2022, with a 5-year trough of -$342.6 million in FY2024.
  • In the last 3 years, Lyell Immunopharma's EBITDA had a median value of -$227.1 million in 2023 and averaged -$252.9 million.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 58.75% in 2020, then climbed by 24.99% in 2022.
  • Lyell Immunopharma's EBITDA (Yearly) stood at -$204.7 million in 2020, then fell by 23.17% to -$252.1 million in 2021, then grew by 24.99% to -$189.1 million in 2022, then declined by 20.11% to -$227.1 million in 2023, then crashed by 50.84% to -$342.6 million in 2024.